ºÚÁÏÍø

Journal of Pharmacokinetics & Experimental Therapeutics
ºÚÁÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Review Article   
  • J Pharmacokinet Exp Ther 2022, Vol 6(6): 156
  • DOI: 10.4172/jpet.1000156

Dalfampridine: Review Analysis on Multiple Sclerosis and Parkinson?s disease related to Waking Disability

Taslim Shaikh*
Parmaceutical Department, Shivlingeshwar Collage of Pharmacy, Almala, Latur, Maharashtra, India
*Corresponding Author : Taslim Shaikh, Parmaceutical Department, Shivlingeshwar Collage of Pharmacy, Almala, Latur, Maharashtra, India, Email: shaikhtslim786@gmail.com

Received Date: Nov 29, 2022 / Accepted Date: Dec 26, 2022 / Published Date: Dec 27, 2022

Abstract

The Multiple sclerosis and Parkinson’s disease are neurodegenerative disease which effect on the central nervous system. Which loss the coordination between brain and body multiple sclerosis is the progressive, autoimmune disease. It occurs when your immune system attack myelin cell in your brain and spinal cord. Parkinson’s disease is caused by the loss of dopamine in a part of your brain called substantial nigra, which causes and cure are unknown. MS disease are commonly occurs in young adult i.e. 20to 40 years where as Parkinson’s disease commonly occurs in old persons i.e. 60 years. Both the disease do not occur in same person, both disease loss the coordination of brain and body related to gait dysfunction. Dalfampridine is one of the available treatments for to improve the walking in MS and Parkinson’s disease related to gait dysfunction. Dalfampridine is the oral potassium channel blocker which was recently approved by FDA for sympathomimetic treatment in MS. Dalfampridine which acts on central and peripheral nervous system enhances conduction in demyelinated axon and improves waking ability of MS patient.

Citation: Shaikh T (2022) Dalfampridine: Review Analysis on Multiple Sclerosisand Parkinson’s disease related to Waking Disability. J Pharmacokinet Exp Ther6: 156. Doi: 10.4172/jpet.1000156

Copyright: © 2022 Shaikh T. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top